Immunoallergic drug-induced liver injury in humans

Seminars in Liver Disease

Volumn 29, Issue 4, 2009, Pages 383-392

  Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autoimmunity; Hepatitis; Idiosyncratic drug reaction; Metabolic idiosyncrasy

Indexed keywords

APLASTIC ANEMIA; ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; DRUG INDUCED DISEASE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LIVER INJURY; LIVER TOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AUTOIMMUNITY; DISEASE SUSCEPTIBILITY; DRUG THERAPY; DRUG-INDUCED LIVER INJURY; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 70449117614     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1240007     Document Type: Article

References (91)

1. Ostapowicz G, Fontana R J., Schidt F V. et al, U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002 137 (12) 947-954
2. Watkins P B., Kaplowitz N, Slattery J T. et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006 296 (1) 87-93
3. Park B K., Kitteringham N R., Maggs J L., Pirmohamed M, Williams D P. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005 45 177-202
4. Walgren J L., Mitchell M D., Thompson D C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005 35 (4) 325-361
5. Lerch M, Pichler W J. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol 2004 4 (5) 411-419
6. Roujeau J C. Immune mechanisms in drug allergy. Allergol Int 2006 55 (1) 27-33
7. Martin A M., Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B, 5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004 101 (12) 4180-4185
8. Warkentin T E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003 121 (4) 535-555
9. Petz L D. Drug-induced autoimmune hemolytic anemia. Transfus Med Rev 1993 7 (4) 242-254
10. Young N S., Scheinberg P, Calado R T. Aplastic anemia. Curr Opin Hematol 2008 15 (3) 162-168
11. Roth R A., Luyendyk J P., Maddox J F., Ganey P E. Inflammation and drug idiosyncrasyis there a connection? J Pharmacol Exp Ther 2003 307 (1) 1-8
12. Zimmerman H. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver 2nd ed. Philadelphia, PA Lippincott Williams & Wilkins 1999
13. Huang Y S., Chern H D., Su W J. et al. Polymorphism of the N -acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002 35 (4) 883-889
14. Lawrenson R A., Seaman H E., Sundstrm A, Williams T J., Farmer R D. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 2000 23 (4) 333-349
15. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007 47 513-539
16. Tostmann A, Boeree M J., Aarnoutse R E., de Lange W C., van der Ven A J., Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008 23 (2) 192-202
17. Kindmark A, Jawaid A, Harbron C G. et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008 8 (3) 186-195
18. Andrade R J., Lucena M I., Alonso A et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004 39 (6) 1603-1612
19. Ungo J R., Jones D, Ashkin D et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998 157 (6 Pt 1) 1871-1876
20. Clay K D., Hanson J S., Pope S D., Rissmiller R W., Purdum P P. III, Banks P M. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006 144 (6) 415-420
21. Zimpfer A, Propst A, Mikuz G, Vogel W, Terracciano L, Stadlmann S. Ciprofloxacin-induced acute liver injury: case report and review of literature. Virchows Arch 2004 444 (1) 87-89
22. Bougie D W., Wilker P R., Wuitschick E D. et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002 100 (6) 2071-2076
23. Thiim M, Friedman L S. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis 2003 7 (2) 381-399, vivii
24. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 1999 28 (6) 392-397
25. Uetrecht J P., Woosley R L. Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 1981 6 (2) 118-134
26. Black M, Mitchell J R., Zimmerman H J., Ishak K G., Epler G R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975 69 (2) 289-302
27. Chalasani N, Fontana R J., Bonkovsky H L. et al, Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008 135 (6) 1924-1934, 1934, e1e4
28. Keisu M, Andersson T B. Drug-induced liver injury in humans: the case of ximelagatran In: Uetrecht JP Mechanisms of Adverse Drug Reactions. Heidelberg, Germany Springer-Verlag In press
29. Polak B CP, Wesseling H, Schut D, Herxheimer A, Meyler L. Blood dyscrasias attributed to chloramphenicol. A review of 576 published and unpublished cases. Acta Med Scand 1972 192 (5) 409-414
30. Keohane E M. Acquired aplastic anemia. Clin Lab Sci 2004 17 (3) 165-171
31. Waldhauser L, Uetrecht J. Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat. Toxicology 1996 114 (2) 155-162
32. Lawson T M., Amos N, Bulgen D, Williams B D. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2001 40 (3) 329-335
33. Warkentin T E., Kelton J G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001 344 (17) 1286-1292
34. Maddrey W C., Boitnott J K. Isoniazid hepatitis. Ann Intern Med 1973 79 (1) 1-12
35. Tahaolu K, Ata G, Sevim T et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001 5 (1) 65-69
36. Pellock J M. Felbamate. Epilepsia 1999 40 (Suppl 5) S57-S62
37. Bourdi M, Chen W, Peter R M. et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996 9 (7) 1159-1166
38. Martin J L., Kenna J G., Martin B M., Thomassen D, Reed G F., Pohl L R. Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. Hepatology 1993 18 (4) 858-863
39. Watkins P B. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005 33 (1) 1-5
40. Eksteen B, Afford S C., Wigmore S J., Holt A P., Adams D H. Immune-mediated liver injury. Semin Liver Dis 2007 27 (4) 351-366
41. Manns M P., Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006 43 (2, Suppl 1) S132-S144
42. Rotmensch H H., Yust I, Siegman-Igra Y, Liron M, Ilie B, Vardinon N. Granulomatous hepatitis: a hypersensitivity response to procainamide. Ann Intern Med 1978 89 (5 Pt 1) 646-647
43. Lewis J H., Zimmerman H J., Benson G D., Ishak K G. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 1984 86 (3) 503-513
44. Salazar-Pramo M, Rubin R L., Garca-De La Torre I. Systemic lupus erythematosus induced by isoniazid. Ann Rheum Dis 1992 51 (9) 1085-1087
45. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996 312 (7024) 169-172
46. Dupont A, Six R. Lupus-like syndrome induced by methyldopa. Br Med J (Clin Res Ed) 1982 285 (6343) 693-694
47. Liu Z X., Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002 6 (3) 455-474
48. Murphy W G., Kelton J G. Methyldopa-induced autoantibodies against red blood cells. Blood Rev 1988 2 (1) 36-42
49. Perry H M. Jr. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 1973 54 (1) 58-72
50. Selroos O, Edgren J. Lupus-like syndrome associated with pulmonary reaction to nitrofurantoin. Report of three cases. Acta Med Scand 1975 197 (1-2) 125-129
51. Sharp J R., Ishak K G., Zimmerman H J. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980 92 (1) 14-19
52. Levy M. Propylthiouracil hepatotoxicity. A review and case presentation. Clin Pediatr (Phila) 1993 32 (1) 25-29
53. Takuwa N, Kojima I, Ogata E. Lupus-like syndromea rare complication in thionamide treatment for Graves' disease. Endocrinol Jpn 1981 28 (5) 663-667
54. Kurtz M D. Migratory polyarthritis occurring with methimazole therapy. N Y State J Med 1968 68 2810-2811
55. Fischer M G., Nayer H R., Miller A. Methimazole-induced jaundice. JAMA 1973 223 (9) 1028-1029
56. McCraken M, Benson E A., Hickling P. Systemic lupus erythematosus induced by aminoglutethimide. BMJ 1980 281 (6250) 1254
57. Stuart-Harris R C., Smith I E. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 1984 11 189-204
58. Kramer M R., Levene C, Hershko C. Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy. Scand J Haematol 1986 36 (1) 118-120
59. Scully L J., Clarke D, Barr R J. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993 38 (4) 744-751
60. Choi H K., Merkel P A., Niles J L. ANCA-positive vasculitis associated with allopurinol therapy. Clin Exp Rheumatol 1998 16 (6) 743-744
61. Chawla S K., Patel H D., Parrino G R., Soterakis J, Lopresti P A., D'Angelo W A. Allopurinol hepatotoxicity. Case report and literature review. Arthritis Rheum 1977 20 (8) 1546-1549
62. Ecker J A. Phenylbutazone hepatitis. Am J Gastroenterol 1965 43 23-29
63. Farid N, Anderson J. S.L.E.-like reaction after phenylbutazone. Lancet 1971 1 (7707) 1022-1023
64. Brown M, Schubert T. Phenytoin hypersensitivity hepatitis and mononucleosis syndrome. J Clin Gastroenterol 1986 8 (4) 469-477
65. Ross S, Ormerod A D., Roberts C, Dwyer C, Herriot R. Subacute cutaneous lupus erythematosus associated with phenytoin. Clin Exp Dermatol 2002 27 (6) 474-476
66. Bateman D E. Carbamazepine induced systemic lupus erythematosus: case report. Br Med J (Clin Res Ed) 1985 291 (6496) 632-633
67. Morales-Diaz M, Pinilla-Roa E, Ruiz I. Suspected carbamazepine-induced hepatotoxicity. Pharmacotherapy 1999 19 (2) 252-255
68. Dujovne C A., Chan C H., Zimmerman H J. Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med 1967 277 (15) 785-788
69. Hoffman B J. Sensitivity to sulfadiazine resembling acute lupus erythematosus. Arch Dermatol Syph 1945 51 190-192
70. Alberti-Flor J J. Chlorpromazine-induced lupus-like illness. Am Fam Physician 1983 27 (4) 151-152
71. Russell R I., Allan J G., Patrick R. Active chronic hepatitis after chlorpromazine ingestion. BMJ 1973 1 (5854) 655-656
72. Bonsmann G, Schiller M, Luger T A., Stnder S. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001 44 (6) 925-931
73. Fernandes N F., Geller S A., Fong T L. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol 1998 93 (3) 459-460
74. Ahmad S. Lovastatin-induced lupus erythematosus. Arch Intern Med 1991 151 (8) 1667-1668
75. Alla V, Abraham J, Siddiqui J et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006 40 (8) 757-761
76. Marzano A V., Ramoni S, Del Papa N, Barbareschi M, Alessi E. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. Lupus 2008 17 (4) 329-331
77. Sevilla-Mantilla C, Ortega L, Agndez J A., Fernndez-Gutirrez B, Ladero J M., Daz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004 36 (1) 82-84
78. Actis G C., Morgando A, Lagget M, David E, Rizzetto M. Zafirlukast-related hepatitis: report of a further case. J Hepatol 2001 35 (4) 539-541
79. Finkel T H., Hunter D J., Paisley J E., Finkel R S., Larsen G L. Drug-induced lupus in a child after treatment with zafirlukast (Accolate). J Allergy Clin Immunol 1999 103 (3 Pt 1) 533-534
80. Soy M, Ozer H, Canataroglu A, Gumurdulu D, Erken E. Vasculitis induced by zafirlukast therapy. Clin Rheumatol 2002 21 (4) 328-329
81. Mizutani T, Shinoda M, Tanaka Y et al. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab Rev 2005 37 (1) 235-252
82. Uetrecht J P. Drug metabolism by leukocytes, its role in drug-induced lupus and other idiosyncratic drug reactions. Crit Rev Toxicol 1990 20 (4) 213-235
83. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006 368 (9533) 404-418
84. Bowen D G., McCaughan G W., Bertolino P. Intrahepatic immunity: a tale of two sites? Trends Immunol 2005 26 (10) 512-517
85. Sguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003 3 (4) 235-242
86. Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev 2005 4 (5) 309-314
87. Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008 14 (21) 3306-3312
88. Sayeh E, Uetrecht J P. Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: failure of the Th1/Th2 paradigm. Toxicology 2001 163 (2-3) 195-211
89. Fouser L A., Wright J F., Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 2008 226 87-102
90. Diveu C, McGeachy M J., Cua D J. Cytokines that regulate autoimmunity. Curr Opin Immunol 2008 20 (6) 663-668
91. Roark C L., Simonian P L., Fontenot A P., Born W K., O'Brien R L. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol 2008 20 (3) 353-357